Trial Profile
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Dec 2022
Price :
$35
*
At a glance
- Drugs Erenumab (Primary)
- Indications Migraine
- Focus Registrational; Therapeutic Use
- Acronyms ARISE
- Sponsors Amgen
- 09 Nov 2022 Results of cost effectiveness analysis from NCT02066415, STRIVE, ARISE, LIBERTY and HER-MES presented at the 25th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
- 08 Feb 2022 Results from ARISE and STRIVE assessing the changes in the functional impact of migraine following treatment with erenumab, as measured by the Migraine Functional Impact Questionnaire, published in the Headache.
- 20 Dec 2021 Results of post-hoc secondary analysis of NCT01952574, NCT02456740, NCT02483585, NCT02066415, and NCT02174861 assessing the efficacy and safety profiles of erenumab in patients with migraine with aura, published in the JAMA Neurology.